Jiwa Laura S, van Diest Paul J, Hoefnagel Laurien D, Wesseling Jelle, Wesseling Pieter, Moelans Cathy B
Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, PO Box 85500, Utrecht 3508GA, The Netherlands.
BMC Cancer. 2014 Nov 22;14:864. doi: 10.1186/1471-2407-14-864.
Several studies have shown that the immunophenotype of distant breast cancer metastases may differ significantly from that of the primary tumor, especially with regard to differences in the level of hormone receptor protein expression, a process known as receptor conversion. This study aimed to compare expression levels of several membrane proteins between primary breast tumors and their corresponding distant metastases in view of their potential applicability for molecular imaging and drug targeting.
Expression of Claudin-4, EGFR, CAIX, GLUT-1 and IGF1R was assessed by immunohistochemistry on tissue microarrays composed of 97 paired primary breast tumors and their distant (non-bone) metastases.
In both the primary cancers and the metastases, Claudin-4 was most frequently expressed, followed by GLUT-1, CAIX and EGFR.From primary breast cancers to their distant metastases there was positive to negative conversion, e.g. protein expression in the primary tumor with no expression in its paired metastasis, in 6%, 19%, 12%, 38%, and 0% for Claudin-4 (n.s), GLUT-1 (n.s), CAIX (n.s), EGFR (n.s) and IGF1R (n.s) respectively. Negative to positive conversion was seen in 65%, 47%, 43%, 9% and 0% of cases for Claudin-4 (p = 0.049), GLUT-1 (p = 0.024), CAIX (p = 0.002), EGFR (n.s.) and IGF1R (n.s.) respectively. Negative to positive conversion of Claudin-4 in the metastasis was significantly associated with tumor size (p = 0.015), negative to positive conversion of EGFR with negative PR status (p = 0.046) and high MAI (p = 0.047) and GLUT-1 negative to positive conversion with (neo)adjuvant chemotherapy (p = 0.039) and time to metastasis formation (p = 0.034). CAIX and GLUT-1 expression in the primary tumor were significantly associated with high MAI (p = 0.008 and p = 0.038 respectively).
Claudin-4 is frequently expressed in primary breast cancers but especially in their metastases and is thereby an attractive membrane bound molecular imaging and drug target. Conversion in expression of the studied proteins from the primary tumor to metastases was fairly frequent, except for IGF1R, implying that the expression status of metastases cannot always be reliably predicted from the primary tumor, thereby necessitating biopsy for reliable assessment.
多项研究表明,远处乳腺癌转移灶的免疫表型可能与原发肿瘤有显著差异,尤其是在激素受体蛋白表达水平上存在差异,这一过程称为受体转换。本研究旨在比较原发性乳腺肿瘤与其相应远处转移灶中几种膜蛋白的表达水平,以探讨其在分子成像和药物靶向方面的潜在适用性。
通过免疫组织化学方法,在由97对原发性乳腺肿瘤及其远处(非骨)转移灶组成的组织微阵列上评估Claudin-4、表皮生长因子受体(EGFR)、碳酸酐酶IX(CAIX)、葡萄糖转运蛋白1(GLUT-1)和胰岛素样生长因子1受体(IGF1R)的表达。
在原发性癌和转移灶中,Claudin-4的表达最为常见,其次是GLUT-1、CAIX和EGFR。从原发性乳腺癌到其远处转移灶存在阳性到阴性的转换,例如原发性肿瘤中有蛋白表达而其配对转移灶中无表达,Claudin-4、GLUT-1、CAIX、EGFR和IGF1R的转换率分别为6%、19%、12%、38%和0%(无统计学意义)。阴性到阳性的转换率分别为Claudin-4 65%(p = 0.049)、GLUT-1 47%(p = 0.024)、CAIX 43%(p = 0.002)、EGFR(无统计学意义)和IGF1R(无统计学意义)。转移灶中Claudin-4的阴性到阳性转换与肿瘤大小显著相关(p = 0.015),EGFR的阴性到阳性转换与孕激素受体(PR)阴性状态(p = 0.046)和高组织学分级(MAI)(p = 0.047)相关,GLUT-1的阴性到阳性转换与(新)辅助化疗(p = 0.039)和转移形成时间(p = 0.034)相关。原发性肿瘤中CAIX和GLUT-1的表达与高MAI显著相关(分别为p = 0.008和p = 0.038)。
Claudin-4在原发性乳腺癌中频繁表达,但在其转移灶中尤其常见,因此是一个有吸引力的膜结合分子成像和药物靶点。除IGF1R外,所研究蛋白从原发性肿瘤到转移灶的表达转换相当频繁,这意味着转移灶的表达状态不能总是从原发性肿瘤可靠预测,因此需要活检以进行可靠评估。